InClinica company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Unattributed - IV | Alive

Total Raised


Last Raised

$370K | 4 yrs ago

About InClinica

InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.

InClinica Headquarters Location

701 Lee Road Suite 210

Wayne, Pennsylvania, 19087,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest InClinica News

InClinica and IC LifeSciences Launch Regional Office in Malaysia

Oct 27, 2016

> InClinica and IC LifeSciences Launch Regional Office in Malaysia × InClinica and IC LifeSciences Launch Regional Office in Malaysia 2016-10-27 08:00 -Clinical Research Organisation (CRO) targets rapid development of clinical research studies in the Asia Pacific region KUALA LUMPUR, Malaysia, Oct. 27, 2016 /PRNewswire/ -- InClinica, a contract Clinical Research Organisation (CRO) headquartered in Philadelphia, USA and its subsidiary company, IC LifeSciences launched their Asia Pacific office in Kuala Lumpur recently. The regional office located at Menara KH will serve as a hub for clinical research and life science business development in the Asia Pacific region. From left: Prof. Paul Zimmet, Professor of Diabetes, Monash University; Jeffrey Scott Yablon, Vice President and General Manager, InClinica; Prof. Tan Sri Dato’ Seri Dr. Hj. Mohd. Ismail Merican, Pro-Chancellor and Chairman, MAHSA University; and Datuk Dr. Rahman Ismail, Consulting Medical Director, InClinica. InClinica and IC LifeSciences provide an extensive range of clinical and non-clinical research services through partnerships with both local and international organisations in the pharmaceutical and biotechnology industry. Malaysia is chosen as their regional hub because of its conducive environment for research and life science advancements, apart from its ease of connectivity to the other nations in Asia Pacific. The evening commenced with a warm welcome from Jeffrey S. Yablon, Executive Vice President of InClinica and IC LifeSciences, followed by opening remarks by Tan Sri Dato' Seri Dr. Hj. Mohd. Ismail Merican, Pro-Chancellor and Chairman of MAHSA University. About 40 guests from the research industry and academia were present to mark the occasion. "Today's launch represents our continued growth and commitment to building a sustainable and growing organisation in the region," said Jeff Yablon. "By setting up base in Malaysia, we believe we will be able to advance the clinical research landscape via knowledge transfer and sharing. We are excited about the massive potential in the Asia Pacific region which remains untapped, and look forward to rapid progress within the next three years. " "Non-communicable diseases such as diabetes, hypertension, and obesity are rising at alarming rates in this part of the world due to industrialisation and fast-paced lifestyles. As such, clinical research is a vital aspect of medical advancement to combat these diseases and others such as infectious diseases," said Tan Sri Dr. Ismail. "We are pleased that InClinica has chosen Malaysia as its regional base, which will put us first in line in the discovery of innovative medical advancements. " InClinica also has offices in the United Kingdom, Australia and Greece. The management team boasts over 100 years of combined experience in drug and device development across diverse therapeutic areas. Through IC LifeSciences, InClinica will be collaborating with MyBioScienceLab in Malacca, which provides chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices and cosmetics. About InClinica ( ) InClinica, headquartered in Philadelphia, USA, is a global clinical contract research organization that works on all phases of clinical development. The company was established in 2016 following the acquisition of an existing global CRO by private equity firm, Velocity Fund Partners. InClinica is spearheaded by a management team with over 100 years of combined experience in drug and device development across diverse therapeutic areas. In addition to the U.S. and Malaysia, InClinica also has offices in the U.K., Australia, and Greece. About IC LifeSciences IC LifeSciences is a subsidiary company targeting global business development opportunities in the healthcare and life science industry. Founded in 2016, IC LifeSciences offers innovative science-driven products and services in multiple therapeutic areas. Currently, IC LifeSciences collaborates with testing facilities, MyBioScienceLab (Malacca) and Gateway Analytical (Pittsburgh, Pennsylvania), to provide chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices, and cosmetics.

  • Where is InClinica's headquarters?

    InClinica's headquarters is located at 701 Lee Road, Wayne.

  • What is InClinica's latest funding round?

    InClinica's latest funding round is Unattributed - IV.

  • How much did InClinica raise?

    InClinica raised a total of $5.57M.

  • Who are the investors of InClinica?

    Investors of InClinica include Velocity Fund Partners.

  • Who are InClinica's competitors?

    Competitors of InClinica include EUSA Pharma, Deciphera Pharmaceuticals, Nutrinia, GC-Rise Pharmaceutical, LIDDS and 11 more.

You May Also Like

Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.


PhytoCeutica seeks to discover and develop botanical drugs for serious, untreated medical conditions. It does this through the utilization of a assay and informatics platform, as well as through controlled clinical trials.

Chakshu Research

Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.